Overview

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Status:
Not yet recruiting
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
To learn if adding lurbinectedin to the combination of paclitaxel and bevacizumab can help to control advanced cancer.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Jazz Pharmaceuticals
Treatments:
Bevacizumab
Paclitaxel